采用卵巢癌风险算法(ROCA)进行卵巢癌筛查:有益、有害还是仅仅昂贵?
基于英国卵巢癌筛查协作试验(UKCTOCS)构建马尔可夫模型,预测ROCA筛查从50岁至85岁的卵巢癌死亡率为0.954%,人均预期寿命减少0.178年。模型预测的死亡率下降与UKCTOCS相似(11% vs 10%)。50岁起筛查20年可降低卵巢癌死亡率6%,每生命年成本585,946美元;筛查30年降低9%,每生命年成本763,970美元。结论认为ROCA能改善早期卵巢癌检测,但对平均风险人群筛查不实用且成本高昂。
要点
- 基于UKCTOCS的马尔可夫模型预测ROCA筛查可降低卵巢癌死亡率6%至9%。
- 50岁起筛查20年每生命年成本585,946美元,筛查30年每生命年成本763,970美元。
- 模型支持FDA对ROCA试验的批评,认为卵巢癌筛查可能降低死亡率但不具成本效益。
核心结论
- ROCA检测能改善早期卵巢癌的检测,但对平均风险人群的筛查不实用。
- 模型预测ROCA检测可将卵巢癌总死亡率降低6%至9%,但成本高昂。
- ROCA要变得实用,成本需降低十倍,且对卵巢癌死亡率仅有边际影响。
- 该模型支持FDA对ROCA检测的批评,卵巢癌筛查可能降低死亡率但不具成本效益。
研究设计与样本
- 基于英国卵巢癌筛查协作试验(UKCTOCS)构建马尔可夫模型,用于预测ROCA筛查卵巢癌的结果。
主要发现
- 模型预测50岁至85岁的卵巢癌死亡率为0.954%,人均预期寿命减少0.178年。
- 使用UKCTOCS数据,模型预测的死亡率下降相似(11% vs 10%),卵巢癌死亡率曲线相似。
- 50岁起筛查20年将卵巢癌死亡率从0.953%降至0.898%,绝对下降6%,预期寿命增加0.0101年,每10万筛查者预防55例死亡,每生命年成本585,946美元。
- 筛查30年将死亡率从0.954%降至0.872%,绝对下降9%,预防82例死亡,每生命年成本763,970美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To measure the effectiveness of ovarian cancer screening using the Risk of Ovarian Cancer Algorithm (ROCA). METHODS: A Markov model was constructed based on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). This model was used to predict the outcome of ovarian cancer screening with ROCA. RESULTS: The model predicted the ovarian cancer mortality from age 50 to age 85 to be 0.954% with a decrease in life expectancy of 0.178years (yrs) per person. Using data from the UKCTOCS the model predicted a similar reduction in mortality (11% vs. 10%), and similar curves for ovarian cancer mortality. Screening at age 50 for 20yrs reduced ovarian cancer mortality from 0.953% to 0.898%, an absolute decrease of 6%, yielding an increase in life expectancy of 0.0101yrs, preventing 55 deaths per 100,000 screened at a cost of $585,946 per life-yr. Screening for 30yrs reduced mortality from 0.954% to 0.872%, an absolute decrease of 9%, preventing 82 deaths at a cost of $763,970 per life-yr. CONCLUSION: The ROCA test can improve the detection of early ovarian cancer but is not practical for screening in an average-risk population. We predict the ROCA test will reduce overall ovarian cancer mortality by 6% to 9% but at a substantial cost. For ROCA to be practical, the cost would need to be reduced ten-fold and would have only a marginal impact on mortality from ovarian cancer. This model supports the FDA's criticism of the ROCA test. Ovarian cancer screening may reduce mortality from ovarian cancer but is not cost effective.
引用
- Naumann RW, Brown J. Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive? Gynecol Oncol. 2018. PMID: 29398069. doi:10.1016/j.ygyno.2018.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。